pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma

Autor: Whitney B. Pope, Catalina Raymond, Ararat Chakhoyan, Matthew Ji, Caleb Tan, Timothy F. Cloughesy, Jacob Schlossman, Linda M. Liau, Benjamin M. Ellingson, Albert Lai, Noriko Salamon, Jingwen Yao, Phioanh L. Nghiemphu
Rok vydání: 2019
Předmět:
Male
Cancer Research
pH-weighted imaging
Neurology
Imaging biomarker
Image Processing
Recurrent GBM
Antineoplastic Agents
Immunological
Computer-Assisted
0302 clinical medicine
Image Processing
Computer-Assisted
Treatment Failure
Prospective Studies
Amines
Prospective cohort study
Cancer
Echo-Planar Imaging
Hydrogen-Ion Concentration
Middle Aged
Magnetic Resonance Imaging
Bevacizumab
Immunological
Local
Oncology
030220 oncology & carcinogenesis
Biomedical Imaging
Biomarker (medicine)
Female
CEST
Perfusion
medicine.drug
Adult
medicine.medical_specialty
Oncology and Carcinogenesis
Urology
Neuroimaging
Antineoplastic Agents
Article
03 medical and health sciences
Rare Diseases
Clinical Research
medicine
Humans
Oncology & Carcinogenesis
Magnetization transfer
Aged
Proportional hazards model
business.industry
Neurosciences
Brain Disorders
Brain Cancer
Neoplasm Recurrence
Neurology (clinical)
Neoplasm Recurrence
Local
Glioblastoma
business
Biomarkers
030217 neurology & neurosurgery
Follow-Up Studies
Zdroj: Journal of neuro-oncology, vol 142, iss 3
J Neurooncol
ISSN: 1573-7373
0167-594X
DOI: 10.1007/s11060-019-03132-z
Popis: PurposeThe objective of the current study was to explore the efficacy of using pH-weighted amine CEST-EPI as a potential non-invasive imaging biomarker for treatment response and/or failure in recurrent GBM patients treated with bevacizumab.MethodA total of 11 patients with recurrent GBM treated with bevacizumab were included in this prospective study. CEST-EPI, perfusion MRI, and standardized anatomic MRI were obtained in patients before and after bevacizumab administration. CEST-EPI measures of magnetization transfer ratio asymmetry (MTRasym) at 3ppm were used for pH-weighted imaging contrast. Multiple measures were examined for their association with progression-free survival (PFS).ResultTumor acidity, measured with MTRasym at 3ppm, was significantly reduced in both contrast enhancing and non-enhancing tumor after bevacizumab (p = 0.0002 and p
Databáze: OpenAIRE
Externí odkaz: